drugset / Trial / NCT07713732
Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Timeline
- Start
- 2026-07-25
- Primary completion
- 2030-08-29
- Completion
- 2030-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLN-499 | Unknown | — | — |
| Subject | Venetoclax | Small molecule | — | — |